热门资讯> 正文

Abeona以1.55亿美元的价格出售罕见儿科疾病PRV

2025-07-02 23:47

Shares of Abeona Therapeutics (NASDAQ:ABEO) rose on Wednesday after the company said that it has completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), earning $155M on June 27.
The company reported that, after accounting for the sale, its cash, cash equivalents, restricted cash, and short-term investments totaled about $225M as of June 30, 2025.
In April 2025, the U.S. FDA awarded Abeona the PRV following the approval of its gene therapy, Zevaskyn, which is used to treat wounds in both adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
ABEO stock up 8% today.

More on Abeona Therapeutics

Is Abeona Therapeutics' Zevaskyn Worth $3.1m Per Treatment, Or Will Krystal Biotech Remain The Market Leader?
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade)
Abeona Therapeutics Inc. (ABEO) Q1 2025 Earnings Call Transcript
Abeona Therapeutics added to U.S. Small-cap Russell 2000 and Russell 3000 Indexes
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。